ASN 100

Drug Profile

ASN 100

Alternative Names: ASN-1 and ASN-2; ASN-100

Latest Information Update: 19 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Arsanis Biosciences
  • Class Antibacterials; Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Staphylococcal infections

Most Recent Events

  • 14 Mar 2018 The United States Patent and Trademark Office issues Patent No. 9 914 767 for ASN 100 covering cross-neutralising S. aureus toxin antibodies
  • 09 Oct 2017 Additional adverse events and pharmacokinetics data from a phase I trial in Healthy volunteers released by Arsanis
  • 09 Oct 2017 Additional preclinical pharmacodynamics data in Staphylococcal infections released by Arsanis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top